Skip to main content
. 2022 Feb 25;3(3):100534. doi: 10.1016/j.xcrm.2022.100534

Figure 5.

Figure 5

Therapeutic vaccination against T cell lymphoma

(A) Schematic representation of the timeline used for therapeutic vaccination.

(B and C) Assessment of tumor growth volume (B) and survival (C) of animals challenged with the EG.7 tumor following syngeneic therapeutic vaccination using nOVA-/aOVA-pulsed mature DCs. Ctl mice are shown in black, anti-PD-1 in dotted black, DC/nOVA in blue, DC/aOVA in orange, DC/nOVA + anti-PD-1 in green, and DC/aOVA + anti-PD-1 in red.

(D and E) Assessment of tumor growth volume (D) and survival (E) of animals challenged with the EG.7 tumor following allogeneic therapeutic vaccination using nOVA-/aOVA-pulsed mature DCs. Ctl mice are shown in black, anti-PD-1 in dotted black, 300K DC/aOVA in orange, 3K DC/aOVA + anti-PD-1 in purple, 30K DC/aOVA + anti-PD-1 in blue, 100K DC/aOVA + anti-PD-1 in green, and 300K DC/aOVA + anti-PD-1 in red. For all panels, n = 10/group. See also Figure S6.